METiS TechBio, a tech-bio company focused on AI-powered nanodelivery innovation, has successfully listed on the Hong Kong Stock Exchange (HKEX), becoming the world's first publicly listed AI-powered drug delivery company and the first AI-powered large-molecule biopharmaceutical company listed on the Hong Kong market.
With the goal of becoming the "SpaceX of pharmaceuticals," METiS TechBio has, within six years of its founding, become the fastest unicorn in China's AI pharmaceutical sector to reach the IPO milestone.
METiS TechBio's IPO was jointly sponsored by Jefferies, Deutsche Bank Securities Asia and CITIC Securities (Hong Kong). A total of 201,229,000 H shares were offered globally, raising over HKD 2.1 billion in proceeds and marking the largest healthcare IPO fundraising in Hong Kong so far in 2026. The Hong Kong public offering was oversubscribed by more than 6,900 times, locking up over HKD 730 billion in subscription funds, representing the highest subscription amount for the Hong Kong public offering among healthcare IPOs in Hong Kong so far in 2026.
METiS TechBio's Hong Kong IPO once again set a record for AI pharmaceutical IPOs in Hong Kong with a top-tier lineup of 18 cornerstone investors subscribing for a total of $148 million, securing comprehensive support from "global asset managers + specialized healthcare funds + AI technology funds + state-level funds + Chinese public fund managers."
METiS TechBio's core competitiveness stems from NanoForge, its proprietary world-first AI nanodelivery platform. The company has built the world's largest ionisable lipid library at the scale of tens of millions, independently developed the world's only algorithm for de novo lipid generation and lipid language model, established the world's first end-to-end lipid and lipid nanoparticle (LNP) screening platform, and created the world's first AI-powered multiscale simulation platform for small-molecule formulation development.
The company has more than 10 pipeline products, including several candidates at the discovery stage, four preclinical candidates, three clinical-stage products, one pre-NDA product, and two animal health products.
